Trice Medical Launches Tenex® 2nd Generation Ultrasonic System, Expanding Minimally Invasive Treatment For Chronic Tendon Paid
Trice Medical announced nationwide commercial availability of the FDA-cleared Tenex® 2nd Generation System, building on the proven Tenex Health TX® platform that has been used in more than 240,000 procedures. The Tenex 2nd Generation System is an advanced platform designed to expand minimally invasive ultrasonic procedures for the treatment of chronic tendon disease and other musculoskeletal conditions, including calcific deposits, bone spurs, and diabetic foot ulcers.
Trice Medical announced nationwide commercial availability of the FDA-cleared Tenex® 2nd Generation System, building on the proven Tenex Health TX® platform that has been used in more than 240,000 procedures. The Tenex 2nd Generation System is an advanced platform designed to expand minimally invasive ultrasonic procedures for the treatment of chronic tendon disease and other musculoskeletal conditions, including calcific deposits, bone spurs, and diabetic foot ulcers.
Alto Neuroscience Announces $120 Million Private Placement Financing
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting offering expenses. The financing is being led by Commodore Capital, with participation from new and existing institutional investors, including Dellora Investments, Driehaus Capital Management, Perceptive Advisors, Spruce Street Capital, Venrock Healthcare Capital Partners, Vestal Point Capital, and a large biotech dedicated investor.
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting offering expenses. The financing is being led by Commodore Capital, with participation from new and existing institutional investors, including Dellora Investments, Driehaus Capital Management, Perceptive Advisors, Spruce Street Capital, Venrock Healthcare Capital Partners, Vestal Point Capital, and a large biotech dedicated investor.
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 million of shares of its common stock at a price of $3.30 per share. Acumen expects to receive gross proceeds from the offering of approximately $35.75 million, before deducting offering expenses.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 million of shares of its common stock at a price of $3.30 per share. Acumen expects to receive gross proceeds from the offering of approximately $35.75 million, before deducting offering expenses.
Honest Health Raises $140 Million to Advance Value-Based Care for Health Systems
Honest Health today announced a $140 million capital raise, led by NewSpring Healthcare, a sector-focused strategy of NewSpring dedicated to partnering with innovative healthcare companies. The investment reflects growing demand for Honest Health's health system-focused approach and its track record of helping organizations execute successfully in value-based payment models.
Honest Health today announced a $140 million capital raise, led by NewSpring Healthcare, a sector-focused strategy of NewSpring dedicated to partnering with innovative healthcare companies. The investment reflects growing demand for Honest Health's health system-focused approach and its track record of helping organizations execute successfully in value-based payment models.
Kandu trial highlights positive outcomes with IpsiHand BCI system
Kandu Health announced positive results from the first randomized controlled trial of its brain-computer interface (BCI) therapy. The trial evaluated its FDA-cleared, non-invasive IpsiHand BCI system in chronic stroke survivors. It detailed outcomes from a post-market randomized controlled study evaluating the clinical performance of IpsiHand. IpsiHand received FDA clearance in 2021 as a breakthrough-designated, 510(k)-cleared device for stroke rehabilitation.
Kandu Health announced positive results from the first randomized controlled trial of its brain-computer interface (BCI) therapy. The trial evaluated its FDA-cleared, non-invasive IpsiHand BCI system in chronic stroke survivors. It detailed outcomes from a post-market randomized controlled study evaluating the clinical performance of IpsiHand. IpsiHand received FDA clearance in 2021 as a breakthrough-designated, 510(k)-cleared device for stroke rehabilitation.
RoundTable Healthcare Partners Invests in Colorscience, a Premium Skincare and Sun Protection Brand
RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, announced a partnership and investment in Colorescience, Inc. which supports the company’s next phase of innovation and growth.
RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, announced a partnership and investment in Colorescience, Inc. which supports the company’s next phase of innovation and growth.
Zarminali Pediatrics Raises $110M Series A To Transform American Pediatric Care
Zarminali Pediatrics, the first outpatient pediatric destination purpose-built to provide integrated primary and specialty care nationwide, today announced a $110M Series A funding round. Healthier Capital led the round, along with participation from existing investor General Catalyst, and new investor K2 HealthVentures.
Zarminali Pediatrics, the first outpatient pediatric destination purpose-built to provide integrated primary and specialty care nationwide, today announced a $110M Series A funding round. Healthier Capital led the round, along with participation from existing investor General Catalyst, and new investor K2 HealthVentures.
Kandu, Inc. Announces Appointment of Marshal Linder to Board of Directors and Strategic Growth Investment from K2 HealthVentures and Piper Sandler Merchant Bank
Kandu, Inc., a healthcare technology company pioneering integrated stroke recovery solutions for post-stroke care, today announced the appointment of Marshal Linder to its Board of Directors. The company also announced the completion of a strategic growth capital investment from K2 HealthVentures and Piper Sandler Merchant Bank, with Toby AuWerter joining the Board in an observer capacity.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that the first participant has been dosed in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug (ACU193) in people with early Alzheimer's disease.
Apella Raises $80 Million in Series B to Transform the Hospital with Ambient AI and Computer Vision
Apella, a health technology company, today announced it raised $80 million in Series B equity and venture debt. The round was led by HighlandX, with returning investors Vensana Capital, Casdin Capital, PFM Health Sciences, Upside Partnership, and Operator Partners, and includes new investors K2 HealthVentures, OpAmp Capital, and Houston Methodist.
Apella, a health technology company, today announced it raised $80 million in Series B equity and venture debt. The round was led by HighlandX, with returning investors Vensana Capital, Casdin Capital, PFM Health Sciences, Upside Partnership, and Operator Partners, and includes new investors K2 HealthVentures, OpAmp Capital, and Houston Methodist.
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced positive results from its Phase 1b signal-seeking study of NMRA-511 in people with Alzheimer’s disease (AD) agitation. NMRA-511, an oral, highly potent, brain-penetrant and selective antagonist of the vasopressin 1a receptor (V1aR) met the goal of the Phase 1b study, demonstrating a clinically meaningful effect size in people with AD agitation. In the study, NMRA-511 demonstrated a favorable tolerability and safety profile with no reports of somnolence or sedation.
Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced positive results from its Phase 1b signal-seeking study of NMRA-511 in people with Alzheimer’s disease (AD) agitation. NMRA-511, an oral, highly potent, brain-penetrant and selective antagonist of the vasopressin 1a receptor (V1aR) met the goal of the Phase 1b study, demonstrating a clinically meaningful effect size in people with AD agitation. In the study, NMRA-511 demonstrated a favorable tolerability and safety profile with no reports of somnolence or sedation.
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that the first participant has been dosed in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug (ACU193) in people with early Alzheimer's disease.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that the first participant has been dosed in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug (ACU193) in people with early Alzheimer's disease.
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - $40 million in non-dilutive capital drawn from Neumora’s existing facility with K2 HealthVentures
Neumora Therapeutics, Inc. a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Neumora today announced that it has drawn an additional $40 million from its existing venture debt facility with K2 HealthVentures. The additional $40 million in non-dilutive capital from this facility drawn, combined with the cash already on the Company’s balance sheet, further strengthens its financial position.
Neumora Therapeutics, Inc. a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Neumora today announced that it has drawn an additional $40 million from its existing venture debt facility with K2 HealthVentures. The additional $40 million in non-dilutive capital from this facility drawn, combined with the cash already on the Company’s balance sheet, further strengthens its financial position.
Mind Medicine Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
MindMed a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing of its previously announced underwritten public offering of 21,131,250 common shares, without par value, which includes the exercise in full by the underwriters of their option to purchase an additional 2,756,250 common shares, at a public offering price of $12.25 per common share. All of the shares were offered by MindMed. The gross proceeds from this offering were approximately $259 million, before deducting underwriting discounts and commissions and offering expenses payable by MindMed.
Mind Medicine a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing of its previously announced underwritten public offering of 21,131,250 common shares, without par value, which includes the exercise in full by the underwriters of their option to purchase an additional 2,756,250 common shares, at a public offering price of $12.25 per common share. All of the shares were offered by MindMed. The gross proceeds from this offering were approximately $259 million, before deducting underwriting discounts and commissions and offering expenses payable by MindMed.
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced positive preclinical data for NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor from three diet-induced obesity (DIO) mouse studies. NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction and 26% in combination with semaglutide.
Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced positive preclinical data for NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor from three diet-induced obesity (DIO) mouse studies. NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction and 26% in combination with semaglutide.
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898. Neumora’s M4 franchise comprises two highly potent and selective M4 muscarinic receptor positive allosteric modulators (PAMs), NMRA-861 and NMRA-898, that may offer an improved therapeutic profile for schizophrenia and other neuropsychiatric disorders over standard of care.
Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898. Neumora’s M4 franchise comprises two highly potent and selective M4 muscarinic receptor positive allosteric modulators (PAMs), NMRA-861 and NMRA-898, that may offer an improved therapeutic profile for schizophrenia and other neuropsychiatric disorders over standard of care.
Alto Neuroscience Announces $50 Million Private Placement Financing
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $50 million, before deducting offering expenses. The financing was led by Perceptive Advisors, with participation by new and existing institutional investors, including Commodore Capital, Vestal Point Capital, Vivo Capital, and a large biotech dedicated investor.
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $50 million, before deducting offering expenses. The financing was led by Perceptive Advisors, with participation by new and existing institutional investors, including Commodore Capital, Vestal Point Capital, Vivo Capital, and a large biotech dedicated investor.
Longevity Health Achieves Top Ratings in CMS Star Quality Measures: A Testament to Excellence in Member Care
Longevity Health is proud to celebrate a significant achievement in its mission to deliver exceptional care to institutionalized members residing within skilled nursing facilities. The Centers for Medicare & Medicaid Services (CMS) awarded three of Longevity's health plans an overall rating – Longevity Health Plan of North Carolina and Longevity Health Plan of Illinois each received the highest possible rating of 5 Stars and Longevity Health Plan of New Jersey received 4 Stars.
MindMed a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing of its previously announced underwritten public offering of 21,131,250 common shares, without par value, which includes the exercise in full by the underwriters of their option to purchase an additional 2,756,250 common shares, at a public offering price of $12.25 per common share. All of the shares were offered by MindMed. The gross proceeds from this offering were approximately $259 million, before deducting underwriting discounts and commissions and offering expenses payable by MindMed.
PHIL Launches Direct-to-Patient 2.0 Platform to Transform Access, Affordability, and Adherence in Pharma
Phil, a leader in patient access solutions for the life sciences industry, today announced the launch of PHIL Direct, its Direct-to-Patient (DTP) 2.0 platform, designed to help pharmaceutical brands meet evolving patient expectations while navigating affordability, compliance, and policy pressures.
Phil, a leader in patient access solutions for the life sciences industry, today announced the launch of PHIL Direct, its Direct-to-Patient (DTP) 2.0 platform, designed to help pharmaceutical brands meet evolving patient expectations while navigating affordability, compliance, and policy pressures.
89bio, Inc. Announces Agreement to be Acquired by Roche
89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has entered into a merger agreement to be acquired by Roche at a price of $14.50 per share in cash at closing, representing a premium of approximately 79% to 89bio’s closing stock price on September 17, 2025, the last trading day before the announcement of the transaction, and a premium of 52% to 89bio’s 60-day volume-weighted average price (VWAP). In addition, 89bio stockholders will receive a non-tradeable CVR to receive certain contingent payments of up to an aggregate of $6.00 per share in cash upon achievement of specified milestones, for a total transaction equity value of up to approximately $3.5 billion on a fully diluted basis. The merger agreement has been unanimously approved by 89bio’s Board of Directors, and 89bio’s Board of Directors unanimously recommends that 89bio stockholders tender their shares in the tender offer.
89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has entered into a merger agreement to be acquired by Roche at a price of $14.50 per share in cash at closing, representing a premium of approximately 79% to 89bio’s closing stock price on September 17, 2025, the last trading day before the announcement of the transaction, and a premium of 52% to 89bio’s 60-day volume-weighted average price (VWAP). In addition, 89bio stockholders will receive a non-tradeable CVR to receive certain contingent payments of up to an aggregate of $6.00 per share in cash upon achievement of specified milestones, for a total transaction equity value of up to approximately $3.5 billion on a fully diluted basis. The merger agreement has been unanimously approved by 89bio’s Board of Directors, and 89bio’s Board of Directors unanimously recommends that 89bio stockholders tender their shares in the tender offer.
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced a collaboration, option and license agreement with JCR Pharmaceuticals (“JCR”) to develop an oligomer-targeted Enhanced Brain Delivery (EBDTM) therapy for Alzheimer’s disease. JCR is a global specialty pharmaceuticals company that applies scientific expertise and unique technologies to research, develop, and deliver next-generation therapies.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced a collaboration, option and license agreement with JCR Pharmaceuticals (“JCR”) to develop an oligomer-targeted Enhanced Brain Delivery (EBDTM) therapy for Alzheimer’s disease. JCR is a global specialty pharmaceuticals company that applies scientific expertise and unique technologies to research, develop, and deliver next-generation therapies.